VOICE-Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease Using Patient-Reported Outcome Measures: A Prospective Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
- 试验地点
- 46
- 主要终点
- To assess time of onset of biologic therapy in pain interference
研究概览
简要总结
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.
详细描述
Vedolizumab (VDZ), a monoclonal antibody that selectively targets intestinal T-cell trafficking, is an effective and safe treatment for moderately to severely active Crohn's disease (CD). Recent evidence from open-label, blinded endpoint studies such as VERSIFY and LOVE-CD provide further support for the efficacy of VDZ in achieving clinical, endoscopic, histologic and radiologic disease improvement in CD. Despite these data, VDZ is generally perceived to have a slower onset of action than other biologics, including tumor necrosis factor (TNF) antagonists and the interleukin (IL)-12/23 antagonist, ustekinumab (UST). The IL-23 antagonist risankizumab (RISA) has been more recently approved for treatment of CD and post-hoc analyses of SEQUENCE trial data showed RISA to be superior to UST for inducing clinical remission at Week 24, and thus, RISA may also be considered to have a quicker onset of action than VDZ. This perception largely emanates from the results of the VDZ pivotal for CD (GEMINI 2) where efficacy was assessed at Week 6 after only 2 doses in a largely refractory population. However, in clinical practice VDZ induction consists of 3 doses of VDZ 300 mg administered intravenously at weeks 0, 2 and 6 instead of the 2 doses used in the pivotal trials. In recent clinical trials, induction endpoints for therapeutics in CD are now typically measured at least after Week 12. Accordingly, it is uncertain whether the generally held perception of a relatively slow onset of action for VDZ is accurate. Moreover, it should also be noted that the perception of a slow onset of action has also been conflated to infer that VDZ is a relatively less effective induction therapy in CD than TNF antagonists or UST. Further data to evaluate these issues are needed.
Rapidity of symptom resolution, which is commonly used as a surrogate for speed of onset, is a priority for patients and clinicians. It is therefore important to better understand the kinetics of symptom improvement captured using patient-reported outcomes (PROs) in patients initiating VDZ for treatment of CD.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is an adult 18 years of age or older with confirmed CD, as per standard clinical criteria which may include symptoms, endoscopy, histopathology, and imaging.
- •Participant has active CD and has been prescribed as standard of care (SOC) and is planned to start VDZ or IL-23 antagonist therapy (UST, RISA, or GUS or MIR [if approved for the treatment of CD during the recruitment period for this study]) for the first time in accordance with the product label, as determined by the treating physician.
- •Participant has a baseline PROMIS Pain Interference-SF score ≥ 15 (corresponding T-score ≥ 55) (PROMIS Pain Interference-SF 8a [V1.1]).
- •a. Score is calculated by adding score (1 to 5) for each of the 8 subcomponents.
- •Participant has completed all SOC biologic work-up assessments (this may include assessment of tuberculosis, chronic infections, Clostridioides difficile infection and vaccination status per local practice).
- •Ability of participant to participate fully in all aspects of this observational study. Full comprehension of consent language and informed consent must be obtained from the participant and documented.
排除标准
- •Participant has CD-related surgery planned or anticipated during the study.
- •Participant has prior exposure to an advanced therapy for the treatment of CD (biologic or small molecule) other than an anti-TNF (i.e., anti-integrin, anti-IL, Janus kinase inhibitors, or sphingosine-1-phosphate receptor 1). Prior failure or intolerance to 2 or more anti-TNF (i.e., infliximab, adalimumab, or certolizumab pegol) therapies in the past 3 years is also cause for exclusion.
- •Participant has an active infection at baseline requiring intravenous systemic antibiotics.
- •Note: The treating physician must have completed all appropriate baseline screening tests as per the product label.
- •Participant has evidence of C. difficile toxin or is prescribed treatment for C. difficile infection, or other intestinal bacterial pathogen, ≤ 2 weeks prior to Screening.
- •Participant has chronic non-inflammatory bowel disease pain.
研究组 & 干预措施
IL-23 Antagonists
Group two will include participants who will be starting an IL-23 antagonist as part of routine care.
Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider.
干预措施: Guselkumab (GUS) (Drug)
IL-23 Antagonists
Group two will include participants who will be starting an IL-23 antagonist as part of routine care.
Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider.
干预措施: Mirikizumab (MIR) (Drug)
Vedolizumab
Group one will include participants who will be starting Vedolizumab as part of routine care.
Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider.
干预措施: Vedolizumab (VDZ) (Drug)
IL-23 Antagonists
Group two will include participants who will be starting an IL-23 antagonist as part of routine care.
Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider.
干预措施: Risankizumab (RISA) (Drug)
IL-23 Antagonists
Group two will include participants who will be starting an IL-23 antagonist as part of routine care.
Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider.
干预措施: Ustekinumab (UST) (Drug)
结局指标
主要结局
To assess time of onset of biologic therapy in pain interference
时间窗: Baseline to Week 14
Time to meaningful clinical improvement in pain interference, defined as a ≥ 2-point decrease in the PROMIS Pain Interference-SF T-score
次要结局
- To assess time of onset of biologic therapy in multiple QOL and functioning domains(Baseline to Weeks 14, 30, and 52)
- To assess the efficacy of therapy in inducing a meaningful clinical improvement in pain interference through Week 52 through a reduction in PROMIS - Pain Interference - Short Form Scores.(Baseline to Weeks 14, 30, and 52)
- To assess early change in patient-reported symptoms within the PRO-2 through Week 14.(Baseline to Week 14)
- To assess early change in patient-reported symptoms within the PROMIS - Pain Interference - Short Form through Week 14(Baseline to Week 14)
- To assess the efficacy of therapy in inducing a meaningful clinical improvement in fatigue through Week 52 through a reduction in PROMIS - Fatigue - Short Form Scores.(Baseline to Weeks 14, 30, and 52)
- To assess the efficacy of therapy in inducing a meaningful clinical improvement in anxiety through Week 52 through a reduction in PROMIS - Emotional Distress - Anxiety - Short Form Scores.(Baseline to Weeks 14, 30, and 52)
- To assess the efficacy of therapy in inducing a meaningful clinical improvement in depression through Week 52 through a reduction in PROMIS Emotional Distress - Depression - Short Form.(Baseline to Weeks 14, 30, and 52)
- To assess the efficacy of therapy in inducing a meaningful clinical improvement in sleep disturbance through Week 52 through a reduction in PROMIS - Sleep Disturbance - Short Form.(Baseline to Weeks 14, 30, and 52)
- To assess the efficacy of therapy in inducing a meaningful clinical improvement in physical function through Week 52 through a reduction in PROMIS - Physical Function - Short Form.(Baseline to Weeks 14, 30, and 52)
- To assess the efficacy of therapy in inducing a meaningful clinical improvement in ability to participate in social roles and activities through Week 52 through a reduction in PROMIS - Ability to Participate in Social Roles and Activities - Short Form.(Baseline to Weeks 14, 30, and 52)
- To assess early change in patient-reported symptoms within the PROMIS - Fatigue - Short Form through Week 14(Baseline to Week 14)
- To assess early change in patient-reported symptoms within the PROMIS - Anxiety - Short Form through Week 14(Baseline to Weeks 2, 6 and 14)
- To assess early change in patient-reported symptoms within the PROMIS - Depression - Short Form through Week 14(Baseline to Weeks 2, 6 and 14)
- To assess early change in patient-reported symptoms within the PROMIS - Sleep Disturbance - Short Form through Week 14(Baseline to Weeks 2, 6 and 14)
- To assess early change in patient-reported symptoms within the PROMIS - Physical Function - Short Form through Week 14(Baseline to Weeks 2, 6 and 14)
- To assess early change in patient-reported symptoms within the PROMIS - Ability to Participate in Social Roles and Activities - Short Form through Week 14(Baseline to Weeks 2, 6 and 14)
- To evaluate the association between the PRO-2 and each PROMIS domain(Baseline to Weeks 14, 30, and 52)
- To assess the efficacy of therapy in resolving patient-reported symptoms by obtaining PRO-2 clinical remission, defined as a stool frequency score ≤ 3 and abdominal pain score ≤ 1 using unweighted subscores through week 52.(Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52)
- To assess the efficacy of therapy in resolving patient-reported symptoms by obtaining PRO-2 clinical response, defined as a decrease in the weighted PRO-2 of ≥ 50% from baseline through week 52.(Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52)
- To assess the efficacy of therapy in resolving fecal urgency defined by a change in UNRS scores from baseline through week 52.(Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52)
- To assess the efficacy of therapy in resolving patient-reported symptoms and improving health related QOL as shown by SIBDQ improvement, defined as ≥ 9-point increase in the SIBDQ from baseline through week 52.(Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52)
- To assess the efficacy of therapy in resolving patient-reported symptoms and improving health related QOL as shown by obtaining SIBDQ remission, defined as an SIBDQ score ≥ 60 through week 52.(Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52)
- To assess the durability of symptom improvement(Baseline to Week 14)
- To assess the efficacy of therapy in resolving patient-reported symptoms by obtaining PRO-2 clinical response through week 52.(Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52)